Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your account with SnapTrade.
Senti issued a press release on April 28, 2025, reporting that “enrollment has been stopped” in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A, conducted in collaboration with Celes Therapeutics (Shanghai) Co. Ltd., “[b]ased on the observation of certain dose limiting toxicities[.]”
Following this news, Senti’s stock price fell over 27% on the same day.